Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schwinger, W; Klass, V; Benesch, M; Lackner, H; Dornbusch, HJ; Sovinz, P; Moser, A; Schwantzer, G; Urban, C.
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients.
Ann Oncol. 2005; 16(7):1199-1206
Doi: 10.1093/annonc/mdi226
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Schwinger Wolfgang
- Co-Autor*innen der Med Uni Graz
- Benesch Martin
- Dornbusch Hans Jürgen
- Lackner Herwig
- Ritter-Sovinz Petra
- Schwantzer Gerold
- Urban Ernst-Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: The administration of high-dose interleukin-2 (IL-2) seems to be a therapeutic option for children with refractory and metastatic solid malignancies. Methods: We prospectively studied treatment-related toxicities, quality of life and laboratory parameters in 10 children with progressive or metastatic solid tumors (metastatic osteosarcoma, n=4; neuroblastoma stage IV, n=3; metastatic Ewing's sarcoma, n=2; metastatic Wilms' tumor, n=1) during IL-2 therapy. Patients were scheduled to receive five cycles of high-dose IL-2 by continuous infusion for 5 days every 3 weeks. Results: All patients developed fever > 39 degrees C and influenza-like symptoms, with a significant decrease in Karnofsky score. In two patients treatment had to be stopped after three cycles because of severe side-effects. During IL-2 therapy a statistical significant increase in white blood cells (WBC), creatinine, gamma-glutamyltransferase, C-reactive protein, glucose and body weight was observed. In contrast, red blood cells, platelets, protein, albumin and cholinesterase significantly decreased. When results from day 1 of the first and of the fifth cycle were compared, an increase of WBC and a decrease of alkaline phosphatase was shown. No constant quantitative changes in total lymphocytes and subsets were observed during IL-2 therapy. Conclusions: IL-2 treatment in children with refractory and relapsed solid malignancies is associated with severe, but reversible, side-effects. However, five of the 10 patients with diseases of worst prognosis could be rescued by this treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Child -
- Child, Preschool -
- Dose-Response Relationship, Drug -
- Feasibility Studies -
- Female -
- Humans -
- Interleukin-2 - administration & dosage Interleukin-2 - therapeutic use
- Male -
- Neoplasms - classification Neoplasms - drug therapy
- Find related publications in this database (Keywords)
- cancer
- children
- interleukin-2
- side-effects
- toxicity